Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factorsn         on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer

A. Lluch

首页> 外文期刊>Annals of Oncology >Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factorsn on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer

【24h】

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factorsn on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer

机译：transGEICAM对21基因复发评分测定法和传统临床病理因素对雌激素受体阳性（ER +）淋巴结阴性乳腺癌妇女辅助临床决策的影响的前瞻性transGEICAM研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Annals of Oncology》 |2012年第3期|p.625-631|共7页
作者
A. Lluch;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献

1. Prospective transGEICAM study of the impact of the 21-gene recurrence score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer [J] . AlbanellJ., GonzálezA., Ruiz-borregoM., Annals of oncology: official journal of the European Society for Medical Oncology . 2012,第3期

机译：transGEICAM的前瞻性研究对21基因复发评分测定法和传统临床病理因素对雌激素受体阳性（ER +）淋巴结阴性乳腺癌妇女辅助临床决策的影响
2. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer. [J] . Partin JF, Mamounas EP Annals of surgical oncology . 2011,第12期

机译：与标准临床病理学指南相比，21基因复发评分分析对淋巴结阴性，雌激素受体阳性乳腺癌的辅助治疗选择的影响。
3. Impact of the 21-Gene Recurrence Score Assay Compared With Standard Clinicopathologic Guidelines in Adjuvant Therapy Selection for Node-Negative, Estrogen Receptor-Positive Breast Cancer [J] . Annals of Surgical Oncology . 2011,第12期

机译：21基因复发评分分析与标准临床病理指南相比对淋巴结阴性，雌激素受体阳性乳腺癌的辅助治疗选择的影响
4. Estrogen Receptor-Positive Breast Cancer: Traditional Prognostics, Molecular Pathology: A New Breast Cancer Taxonomy and 21st Century Personalized Prognostic and Predictive Assays [C] . Frederick L. Baehner International Symposium on Cancer Metastasis and the Lymphovascular system: Basis for Rational Therapy . 2009

机译：雌激素受体阳性乳腺癌：传统预测，分子病理：新的乳腺癌分类和21世纪个性化预测和预测测定
5. Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study [O] . Joseph Gligorov, Xavier B. Pivot, William Jacot, 2015

机译：在雌激素受体阳性早期浸润性乳腺癌女性辅助临床决策中使用21基因检测的前瞻性临床效用研究：SWITCH研究的结果
6. Prospective Study of the Effect of the 21-Gene Assay on Adjuvant Clinical Decision-Making in Japanese Women With Estrogen Receptor-Positive, Node-Negative, and Node-Positive Breast Cancer [O] . Yamauchi Hideko, Nakagawa Chizuko, Takei Hiroyuki, 2014

机译：21基因检测对日本雌激素受体阳性，淋巴结阴性和淋巴结阳性乳腺癌女性辅助临床决策的影响的前瞻性研究

Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factorsn on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer

著录项

引文网络

相似文献

相关主题

期刊订阅